Parkinson's dyskinesia mechanism explained

May 01, 2020

JUPITER, Fla.--May 1, 2020--Many people with Parkinson's disease eventually develop debilitating movements called dyskinesia, a side effect of their much-needed dopamine replacement medication. The mechanism underlying this unwanted side effect has been unknown, until now. An international collaboration led by Scripps Research, Florida has found a key cause, and with it, potentially, a new route to providing relief.

Dopamine replacement therapy makes Parkinson's symptoms much better at first, but eventually treatment gives way to uncontrollable, jerky body movements. But why? New research shows that underlying this development is the therapy's unintended boost of a protein with the unwieldy name Ras-guanine nucleotide-releasing factor 1, or RasGRP1 for short. This boost in RasGRP1 produces a cascade of effects which lead to abnormal, involuntary movements known as LID, or L-DOPA-induced dyskinesia, says co-lead author Srinivasa Subramaniam, PhD, associate professor of neuroscience at Scripps Research, Florida.

Encouragingly, the collaboration found that in dopamine-depleted mice and other animal models, inhibiting production of RasGRP1 in the brain during dopamine replacement diminished the involuntary movements without negating the useful effects of the dopamine therapy.

Taken together, the research offers a new path to easing Parkinson's dyskinesia while allowing maintenance of dopamine replacement therapy, Subramaniam says.

Subramaniam's group has long been interested in cellular signaling in the brain underlying motor movements, and how it is affected by brain diseases, including Huntington's and Parkinson's.

"Parkinson's patients describe treatment-induced dyskinesia as one of the most debilitating features of their illness," Subramaniam says. "These studies show that if we can down-regulate RasGRP1 signaling before dopamine replacement, we have an opportunity to greatly improve their quality of life."

The study, "RasGRP1 is a causal factor in the development of L-DOPA-induced dyskinesia in Parkinson's disease," published in the journal Science Advances May 1. In addition to Subramaniam, the co-lead author is Alessandro Usiello, PhD, of the University of Campania Luigi Vanvitelli, Caserta, Italy, and the Behavioural Neuroscience Laboratory at Ceinge Biotecnologie Avanzate, Naples, Italy.

Dopamine is a neurotransmitter and hormone that plays a key role in movement, learning, memory, motivation, and emotion. Parkinson's develops when dopamine-producing neurons in a region of the mid-brain called the substantia nigra stop working or die. It's a brain region associated with both movement initiation and reward, so its impairment causes a wide variety of symptoms, including stiffness, balance problems, walking difficulty, tremor, depression and memory issues.

Doctors treat Parkinson's with dopamine replacement therapy, often a medicine called levodopa. The brain converts levodopa into dopamine, and at proper doses, this leads to resolution of symptoms. But as dose and duration grow, a side effect called dyskinesia can develop. After a decade, about 95 percent of Parkinson's patients will experience some degree of involuntary dyskinesia, Subramaniam says.

Dyskinesia is different than tremor, according to the Michael J. Fox Foundation.

"It can look like fidgeting, writhing, wriggling, head bobbing or body swaying," the foundation explains. "Many people say they prefer dyskinesia to stiffness or decreased mobility. Others, though, have painful dyskinesia or movements that interfere with exercise or social or daily activities."

The reason for its development has eluded scientists. Subramaniam and his team had studied the problem over the past decade, leading them eventually to the discovery that RasGRP1 signaling was a main culprit.

"There is an immediate need for new therapeutic targets to stop LID, or L-DOPA-induced dyskinesia in Parkinson's disease," Subramaniam says. "The treatments now available work poorly and have many additional unwanted side effects. We believe this represents an important step toward better options for people with Parkinson's."

The next steps in the research will be discovering the best route to selectively reducing expression of RasGRP1 in the striatum while not affecting its expression in other areas of the body, Subramaniam says.

"The good news is that in mice, a total lack of RasGRP1 is not lethal, so we think that blocking RasGRP1 with drugs, or even with gene therapy, may have very little or no major side effects," Subramaniam says.

"It's rare for a nonprofit institution to possess the medicinal chemistry and drug development expertise needed to identify and develop such a therapy, but we have that at Scripps Research," Subramaniam says. "Our next task is to develop suitable compounds capable of blocking RasGRP1 in the striatum."
-end-
In addition to Subramaniam and Usiello, the authors of the study are co-first authors Mehdi Eshraghi, Uri Nimrod Ramírez-Jarquín and Neelam Shahani; Supriya Swarnkar, Nicole Galli, Oscar Rivera, George Tsaprailis, Catherina Scharager-Tapia and Gogce Crynen, all of Scripps Research, Florida; co-authors Tommaso Nuzzo and Arianna De Rosa of the University of Campania Luigi Vanvitelli, Caserta, Italy, and the Behavioural Neuroscience Laboratory at Ceinge Biotecnologie Avanzate, Naples; Qin Li and Erwan Bezard of Motac Neuroscience in Manchester, United Kingdom and the China Academy of Medical Sciences in Beijing, China; and Marie-Laure Thiolat of the Institut des Maladies Neurodegeneratives and the Universite de Bordeaux, Institute des Maladies Neurodegeneratives of Bordeaux, France.

Scripps Research Institute

Related Dopamine Articles from Brightsurf:

Dopamine surge reveals how even for mice, 'there's no place like home'
''There's no place like home,'' has its roots deep in the brain.

New dopamine sensors could help unlock the mysteries of brain chemistry
In 2018, Tian Lab at UC Davis Health developed dLight1, a single fluorescent protein-based biosensor.

Highly sensitive dopamine detector uses 2D materials
A supersensitive dopamine detector can help in the early diagnosis of several disorders that result in too much or too little dopamine, according to a group led by Penn State and including Rensselaer Polytechnic Institute and universities in China and Japan.

Dopamine neurons mull over your options
Researchers at the University of Tsukuba have found that dopamine neurons in the brain can represent the decision-making process when making economic choices.

Viewing dopamine receptors in their native habitat
A new study led by UT Southwestern researchers reveals the structure of the active form of one type of dopamine receptor, known as D2, embedded in a phospholipid membrane.

Significant differences exist among neurons expressing dopamine receptors
An international collaboration, which included the involvement of the research team from the Institut de Neurociències of the UAB (INC-UAB), has shown that neurons expressing dopamine D2 receptors have different molecular features and functions, depending on their anatomical localization within the striatum.

How dopamine drives brain activity
Using a specialized magnetic resonance imaging (MRI) sensor that can track dopamine levels, MIT neuroscientists have discovered how dopamine released deep within the brain influences distant brain regions.

Novelty speeds up learning thanks to dopamine activation
Brain scientists led by Sebastian Haesler (NERF, empowered by IMEC, KU Leuven and VIB) have identified a causal mechanism of how novel stimuli promote learning.

Evidence in mice that childhood asthma is influenced by the neurotransmitter dopamine
Neurons that produce the neurotransmitter dopamine communicate with T cells to enhance allergic inflammation in the lungs of young mice but not older mice, researchers report Nov.

Chronic adversity dampens dopamine production
People exposed to a lifetime of psychosocial adversity may have an impaired ability to produce the dopamine levels needed for coping with acutely stressful situations.

Read More: Dopamine News and Dopamine Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.